Pfizer, danuglipron
Pfizer commits to modified version of its weight-loss drug danuglipron
Pfizer Inc. announced on Thursday that it will move forward with the testing of its modified version of the once-daily weight loss drug danuglipron.
Pfizer targets obesity with new once-daily danuglipron drug
Pfizer announced that it has selected its preferred once-daily modified release formulation of danuglipron, a move that is significant in the obesity drug’s development.
Pfizer moves forward with once-daily weight-loss pill
Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday, after scrapping a twice- daily version of the drug late last year.
Pfizer moving ahead with plans for once-daily weight loss pill
The pharmaceutical giant said clinical evaluation of once-daily doses its oral GLP-1 agonist candidate danuglipron demonstrated "encouraging" data. Dose optimization studies are planned.
Pfizer stock higher on obesity drug challenge to Ozempic, Zepbound
Pfizer is looking to challenge leaders Eli Lilly and Novo Nordisk in the fast-growing market for weight loss drugs. Pfizer shares moved higher in early Thursday trading, putting the stock within touching distance of its highest level of the year ...
Pfizer’s Once-Daily Weight Loss Pill Moves Forward
Pfizer said it saw “encouraging” data from an ongoing early stage trial of its oral weight loss drug, danuglipron.
Pfizer (PFE) Moves Forward With Once-Daily Obesity Pill Study
Pfizer (PFE) is set to move forward with the development of a once-daily formulation of danuglipron, its GLP-1 candidate for obesity.
Pfizer Opts To Move Forward With Once-Daily Danuglipron - Don't Hold Your Breath
Pfizer's weight loss drug danuglipron faces competition in GLP-1 market, but PFE may shift focus to M&A deals for revenue growth. Click here for more on PFE stock.
Pfizer pins hopes on daily pill to crack market for weight-loss drugs
Pharma group seeks to catch up with rivals Eli Lilly and Novo Nordisk in sector projected to be worth $130bn a year
Pfizer advances once-daily weight-loss pill in ongoing study
Pfizer announced that it's advancing its oral weight-loss treatment, called danuglipron, to the next round in an ongoing study after seeing "encouraging" results.
FierceBiotech2d
Pfizer's obesity pill news leaves analysts wanting, biotech investors cheering
Pfizer inadvertently gave a leg up to two obesity biotechs yesterday with the announcement that an extended-release ...
With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs
Pfizer has selected its preferred once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, ...
STAT3d
Pfizer says it will advance once-daily GLP-1 pill after all
Pfizer said Thursday that it plans to advance a new, once-a-day formulation of its experimental obesity drug danuglipron, ...
FierceBiotech3d
Pfizer bounces back in obesity, moving once-daily oral drug toward pivotal trials after earlier missteps
Pfizer has dragged the oral GLP-1 candidate danuglipron back from the brink. Months after dropping one version of the asset ...
Pfizer signals progress on obesity pill, boosting stock
Pfizer’s stock gained ground early Thursday after the drug company said it has taken a step forward in developing a ...
Crain's New York3d
Pfizer advances weight-loss pill in race to lucrative market
Pfizer shares rose nearly 3% before paring back in early trading in New York.
Daily1d
Pfizer advances development of once-daily formulation of Oral GLP-1 Receptor Agonist Danuglipron
Pfizer Inc. has announced that based on results from the ongoing pharmacokinetic study (NCT06153758), the company has ...
Pfizer Inc. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...